Sustainable Growth Advisers 13F: Cuts Danaher (DHR) Stake by $93M

Sustainable Growth Advisers reduced its holdings in Danaher Corporation by 28.4% during the period.

Reviewed by automated data checks against the source filing. How we make and check alerts

Sustainable Growth Advisers sold 421,516 shares from its stake in Danaher Corporation ($DHR), a 28.38% decrease, according to a 13F filing with the SEC dated October 15, 2026. It reported 1,063,782 shares worth $235.68 million at the end of the quarter.

Since the filing, $DHR is down 1.1% to date (from the $231.50 close on Oct 15, 2026).

Find the original: Sustainable Growth Advisers 13F filings on SEC EDGAR

DHR Danaher Corporation
$229.04 +0.00% year to date
Daily close · Oct 16, 2026

Key Points

  • Sustainable Growth Advisers cut its stake in Danaher Corporation (NYSE: DHR) by 421,516 shares, reducing its holdings by 28.4% to a total of 1,063,782 shares valued at $235,680,902 according to a Form 13F filing on October 15, 2026.
  • Other large institutional investors adjusted their positions during the reporting cycle, including Blackrock Inc., which grew its holdings by 3,444,403 shares to end with 55,084,630 shares worth $12,616,583,285.
  • Danaher Corporation trades recently around $228.70, staying above its 50-day moving average of $213.32 as investors look ahead to the company's next earnings report on October 21, 2026.

Get $DHR trade alerts by text

We text you when insiders, Congress or big funds trade $DHR. Free.

Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Danaher Corporation alert may contain errors. Disclosures

Sustainable Growth Advisers reduced its stake in Danaher Corporation (NYSE: DHR) during the period, according to a Form 13F filing submitted to the SEC on October 15, 2026. Institutional 13F filings are backward-looking reports that show holdings from the close of a prior quarter and may not represent the investor's exact position today.

What Changed in Sustainable Growth Advisers's Danaher Position

Sustainable Growth Advisers trimmed its investment by selling off 421,516 shares of Danaher Corporation. That marked a 28.4% decrease from the previous quarter, bringing the firm's total holding down to 1,063,782 shares. The remaining shares had a reported value of $235,680,902 at the time of the filing.

Other Institutional Activity in Danaher

Other major institutional investors made adjustments to their own Danaher positions around the same reporting cycle. Blackrock Inc. grew its holdings by 3,444,403 shares, ending with 55,084,630 shares worth about $12,616,583,285. Vanguard Capital Management LLC added 250,870 shares, lifting its stake by 0.6% to 41,377,076 shares valued at $9,477,005,209. FMR, LLC grew its holdings by 7,006,075 shares, a 31.1% increase that left it with 29,540,895 shares worth $6,766,046,392. State Street Corporation grew its holdings by 560,696 shares, ending with 28,456,019 shares worth $6,517,566,400. Finally, Wellington Management Group, LLP grew its holdings by 1,542,446 shares, a 10.4% increase to 16,316,834 shares worth $3,737,207,549.

Danaher Corporation Stock Up 1.8%

Danaher Corporation shares recently traded around $228.70 as of October 16, 2026. The stock sits above its 50-day moving average of $213.32 and trades higher than its 200-day moving average of $201.33. The share price remains 5.8% below its 52-week high of $242.80 while sitting well above its 52-week low of $160.93.

Recent Earnings

For its trailing twelve-month period, Danaher reported revenue of $25,106,999,296 alongside earnings of $5.61 per share. The company posted a net margin of 15.9% and a return on equity of 7.6%. Revenue grew by 5.5% compared to the same period a year prior. Investors will watch for the company's next earnings report, scheduled for October 21, 2026.

Earnings drift grade

Outlook vs expectations on the last report — not price action.

F 30/100

Reported Apr 21, 2026

  1. Forward outlook

    5 target cuts vs 1 raises.

  2. EPS & revenue

    EPS beat estimates by 5.3%. Revenue missed estimates by 1.8%.

  3. Profit surprise

    EBITDA missed by 22 percent. Operating income missed by 23 percent.

  4. Pre-earnings setup

    Bar was high, analysts already very bullish.

  5. Analyst signal

    1 target raise, 5 target cuts.

  6. Earnings quality

    Gross margin down 1.1 points. Positive free cash flow.

Earnings Call Summary

Danaher started 2026 solidly with adjusted earnings per share of $2.06, up 9.5 percent year over year, beating the consensus of $1.95. Revenue came in at $5.951 billion, slightly below the $6.057 billion expected, due mainly to a lighter respiratory season at Cepheid being down roughly 25 percent. However, strong bioprocessing momentum, with consumables up high single digits and equipment orders surging over 30 percent year over year for the first time in nearly two years, offset weakness. Diagnostics and Life Sciences showed pockets of improvement, with Beckman Coulter diagnostics growing mid single digits outside China and newer products like the Xpert GI panel gaining traction.

Guidance Management raised full year adjusted earnings per share to $8.35 to $8.55 from the prior range. Revenue guidance remains 3 percent to 6 percent growth for the full year, with lower respiratory sales of $1.6 billion to $1.7 billion offset by better core growth elsewhere. Second quarter expected to show low single digit core revenue growth with operating margins around 26.5 percent.

Severe negative reset. The report materially damaged the forward outlook and likely forces major downward revisions.

Dividend

Danaher pays an annual dividend with a yield of 0.69% and a dividend payout ratio of 25.7%.

Insider Buying and Selling at Danaher Corporation

Company insiders also made trades prior to the filing. Director Alan G Spoon sold 1,358 shares on May 1, 2026, at an average price of $174.67 for a total value of $237,207. Chief Executive Officer Rainer M Blair disposed of 58,255 shares on August 21, 2026, totaling $12,736,095.

Analysts Set New Price Targets

Wall Street analysts have updated their views on Danaher. Guggenheim maintained a Buy rating on the stock while raising its price target to $250.00 from $200.00 on October 1, 2026. RBC Capital maintained an Outperform rating and lifted its target to $250.00 from $215.00 on October 5, 2026. Barclays maintained an Overweight rating and raised its target to $255.00 from $230.00 on October 7, 2026. Morgan Stanley maintained an Overweight rating with a target moved to $240.00 from $220.00 on October 13, 2026. TD Cowen maintained a Buy rating and pushed its target to $255.00 from $236.00 on October 13, 2026. Overall, the stock carries a consensus recommendation of strong buy with a mean price target of $244.14 across 22 analyst opinions.

About Danaher Corporation

Headquartered in Washington, DC, Danaher Corporation operates as a science and technology innovator. The firm designs, manufactures, and markets professional, medical, research, and industrial products and services through segments focused on biotechnology, life sciences, and diagnostics. Institutional moves like the one by Sustainable Growth Advisers offer a look at how long-term asset managers handle their stakes in major healthcare names.

Bottom Line

Sustainable Growth Advisers trimmed its stake significantly, but overall institutional interest remains broad as earnings approach on October 21, 2026. Keep in mind that 13F filings are historical snapshots and may not reflect current holdings.

Source: Sustainable Growth Advisers's 13F filing on $DHR (Oct 15, 2026). 13F filings show holdings as of the end of the reporting quarter and may not reflect the fund's current position. Find the original filing: Sustainable Growth Advisers 13F filings on SEC EDGAR. Written by software, not financial advice. How we make alerts

Get $DHR trade alerts by text